• Insilico Medicine won FDA Fast Track designation for ISM6331 in unresectable malignant pleural mesothelioma following prior PD-1 therapy and chemotherapy.
• The designation supports faster development and could enable rolling review, accelerated approval, or priority review if criteria are met.
• ISM6331 is an AI-designed pan-TEAD inhibitor; Phase I data is slated for presentation at ESMO 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607290830PR_NEWS_USPR_____CN13684) on July 29, 2026, and is solely responsible for the information contained therein.